ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,667.20
      0.64%
      US Tech 100
      19,844.80
      -0.01%
      Dow Jones
      40,954.48
      1.85%
      Brent Oil
      83.315
      -1.22%
      Bitcoin
      64,514.17
      -0.53%
      Registration Strip Icon for monitor Customized watchlists with full streaming quotes from leading exchanges, such as NASDAQ, NYSE, AMEX, OTC Markets Small-Cap, LSE and more.
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ

      6. I MAB (IMAB) Quote

      I MAB

      I MAB (IMAB)

      1.63
      0.00
      (0.00%)
      At close: July 16 4:00PM
      Delayed by 15 minutes
      1.63
      0.00
      ( 0.00% )
      After Hours: 5:26PM
      Delayed by 15 minutes

      Empower your portfolio: Real-time discussions and actionable trading ideas.

      Premium

      Key stats and details

      Current Price
      1.63
      Bid
      1.60
      Ask
      1.70
      Volume
      375,248
      1.55 Day's Range 1.64
      0.00 52 Week Range 0.00
      Market Cap
      131.544M
      Previous Close
      1.63
      Open
      1.63
      Last Trade
      1
      @
      1.7
      Last Trade Time
      18:21:40
      Financial Volume
      $ 604,471
      VWAP
      1.6109
      Average Volume (3m)
      -
      Shares Outstanding
      80,701,592
      Dividend Yield
      -
      PE Ratio
      -
      Earnings Per Share (EPS)
      -
      Revenue
      -
      Net Profit
      -

      About I MAB

      I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-actin... I-Mab Biopharma is a clinical-stage biotech company in China that listed on Nasdaq in January 2020. Its first commercial drug will be felzartamab for the China market, a CD38 inhibitor for multiple myeloma, which we estimate will be launched in 2022. Core assets include eftansomatropin, a long-acting recombinant human growth hormone,or rhGH; lemzoparlimab, a potential best-in-class CD47 inhibitor; uliledlimab, a potential best-in-class CD73 inhibitor; and efineptakin alfa, a potential first-in-class long-acting IL-7 drug for tumors and treatment-associated lymphopenia. Show more

      Sector
      Pharmaceutical Preparations
      Industry
      Pharmaceutical Preparations
      Website
      www.i-mabbiopharma.com
      Headquarters
      Grand Cayman, Cym
      Founded
      1970
      I MAB is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker IMAB. The last closing price for I MAB was $1.63. Over the last year, I MAB shares have traded in a share price range of $ 0.00 to $ 0.00.

      I MAB currently has 80,701,592 shares outstanding. The market capitalization of I MAB is $131.54 million.

      IMAB Latest News

      More News

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      July 15 2024
      Edgar (US Regulatory)

      I-Mab Announces Leadership Transitions

      I-Mab Announces Leadership Transitions PR Newswire ROCKVILLE, Md., July 15, 2024 ROCKVILLE, Md., July 15, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company" or "I-Mab"), a U.S.-based...

      July 15 2024
      PR Newswire (US)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      June 06 2024
      Edgar (US Regulatory)

      I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer

      I-Mab Appoints Phillip Dennis, MD, PhD, as Chief Medical Officer PR Newswire ROCKVILLE, Md., June 6, 2024 ROCKVILLE, Md., June 6, 2024  /PRNewswire/ -- I-Mab (NASDAQ: IMAB) (the "Company"), a...

      June 06 2024
      PR Newswire (US)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      June 05 2024
      Edgar (US Regulatory)

      I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers

      I-Mab Announces Collaboration with Bristol Myers Squibb to Evaluate Givastomig in a Combination Study for Newly Diagnosed Gastric and Esophageal Cancers PR Newswire ROCKVILLE, Md., June 5, 2024...

      June 05 2024
      PR Newswire (US)

      Form S-8 - Securities to be offered to employees in employee benefit plans

      May 30 2024
      Edgar (US Regulatory)

      Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]

      May 23 2024
      Edgar (US Regulatory)

      I-Mab Announces Encouraging Phase 1 Clinical Data of PD-L1x4-1BB Bispecific Antibody Ragistomig at ASCO 2024

      Encouraging objective responses were observed in heavily pre-treated patients, including 1 complete response (CR) and 6 partial responses (PR), mainly in patients previously treated with...

      May 23 2024
      GlobeNewswire Inc.

      I-Mab to Participate at the Jefferies Global Healthcare Conference

      I-Mab to Participate at the Jefferies Global Healthcare Conference PR Newswire ROCKVILLE, Md., May 22, 2024 ROCKVILLE, Md., May 22, 2024 /PRNewswire/ -- I-Mab (NASDAQ: IMAB), a U.S.-based global...

      May 22 2024
      PR Newswire (US)
      PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
      10000000DR
      40000000DR
      120000000DR
      260000000DR
      520000000DR
      1560000000DR
      2600000000DR

      Movers

      View all
      • Most Active
      • % Gainers
      • % Losers
      SymbolPriceVol.
      SHIMShimmick Corporation
      $ 3.13
      (51.21%)
      		3.11M
      AFARAura FAT Projects Acquisition Corporation
      $ 16.80
      (34.40%)
      		50.33k
      AFARUAura FAT Projects Acquisition Corporation
      $ 16.50
      (33.82%)
      		1.73k
      AEHRAehr Test Systems
      $ 18.91
      (12.29%)
      		1.84M
      ASSTAsset Entities Inc
      $ 1.7617
      (12.21%)
      		629.65k
      RNLXRenalytix PLC
      $ 0.308
      (-10.44%)
      		26.62k
      SHPWShapeways Holdings Inc
      $ 0.2699
      (-10.03%)
      		102.96k
      PETWag Group Company
      $ 1.40
      (-9.68%)
      		61.9k
      FIVEFive Below Inc
      $ 92.47
      (-9.41%)
      		588.33k
      LVTXLAVA Therapeutics NV
      $ 1.92
      (-9.00%)
      		2.39k
      MAXNMaxeon Solar Technologies Ltd
      $ 0.2388
      (-5.39%)
      		16.67M
      TKLFYoshitsu Company Ltd
      $ 0.6279
      (0.79%)
      		9.04M
      AGRIAgriFORCE Growing Systems Ltd
      $ 0.0813
      (-5.68%)
      		7.79M
      SILOSilo Pharma Inc
      $ 2.33
      (-2.51%)
      		4.68M
      SIRISirius XM Holdings Inc
      $ 3.85
      (-0.77%)
      		4.03M

      IMAB Discussion

      View Posts
      Monksdream Monksdream 1 week ago
      IMAB under $2
      👍️0
      stock1ace1 stock1ace1 3 months ago
      Imab $1.80 golden cross https://schrts.co/CNBigxhc

      I-Mab Price Target Maintained With a $6.00/Share by Needham
      Mentioned: IMAB

      Ratings actions from Benzinga: https://www.benzinga.com/quote/IMAB/analyst-ratings

      (END) Dow Jones Newswires

      April 12, 2024 06:15 ET (10:15 GMT)
      👍️0
      Monksdream Monksdream 3 months ago
      IMAB 10Q due 4/3
      👍️0
      Monksdream Monksdream 4 months ago
      IMAB under $2=
      👍️0
      Monksdream Monksdream 4 months ago
      IMAB under $2
      👍️0
      Monksdream Monksdream 5 months ago
      IMAB under $2
      👍️0
      AGORDON AGORDON 5 months ago
      IMAB
      This is a long-term deal. The China divestiture had to be done to facilitate the future sale of the company. There would be too many Chinese entities to satisfy and hence introduce uncertainty in a future sale. The loss of the Jumpcan deal is a negative because the numbers were spelled out. I will feel much more comfortable about IMAB after they get a Giva or a Uli licensing deal. Combined, based on prior deals for similar drugs would be worth $1B+. It is likely they will have to pay out $30M to the non participants. The $80M from Hangzhou will take years to collect. But, there is one point that has not been addressed. That is the pricing of drugs in China. The Chinese government is notorious for asking for discounts. The pricing of drugs in the USA is better. IMAB has shifted its focus to drugs in a market where they will get much better pricing. The unknown is will IMAB get a deal for Giva, or Uli ?
      👍️0
      AGORDON AGORDON 7 months ago
      2-3 minutes before the close over 500k shares were dumped. Same exercise happened to several Chinese stocks.
      👍️0
      AGORDON AGORDON 7 months ago
      Based on the Astra Zeneca agreement with KYM for their Claudin 18.2 drug, and the Antengene agreement with Calithera for their CD73 inhibitor drug, I estimate that IMAB has potential contracts worth $1.25B+.
      👍️0
      AGORDON AGORDON 7 months ago
      Why doesn't IMAB license Givasgtomig and Ulilidimab? I estimate that the milestone payments would be at least $500M. The share would be at least $5.
      👍️0
      AGORDON AGORDON 7 months ago
      From the 20-F report

      On July 16, 2022, I-Mab Hangzhou entered into a definitive financing agreement with a group of domestic investors in China to raise approximately US$46 million (in RMB equivalent). On the same date, we, through our wholly-owned subsidiary, entered into a shareholders agreement with I-Mab Hangzhou and other domestic investors in I-Mab Hangzhou named therein (the “I-Mab Hangzhou Shareholders Agreement”). Upon the occurrence of certain triggering events as specified in the I-Mab Hangzhou Shareholders Agreement, including but not limited to I-Mab Hangzhou’s failure to accomplish certain public offering condition, we may be obligated to repurchase the equity held by other domestic investors in cash or in our stocks in the period beyond 12 months.
      👍️0
      AGORDON AGORDON 7 months ago
      In the most recent reporting period, Decheng Capital purchased 4 million shares of IMAB.
      👍️0
      AGORDON AGORDON 8 months ago
      The stock has bounced off $1.80 two times within a month.
      👍️0
      AGORDON AGORDON 8 months ago
      Not a surprise to see a pull back from the +50% rise last week. A large order came in at the end of yesterday. Nevertheless, it is disappointing to see the slide. It could fall back to $1.28. Mr. Kannan will be at a conference on 11/14. I think the China approvals will send the stock past $3 next year. The company will be sold by the end of 2025.
      👍️0
      Mt. Blanc Mt. Blanc 8 months ago
      IMAB climbing the charts tracking the $3s. Check it out soon.

      mb
      👍️0
      Monksdream Monksdream 9 months ago
      IMAB under $2
      👍️0

      Your Recent History

      NASDAQ
      IMAB
      I MAB
      Delayed Upgrade Clock